Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Syngene International Ltd. ( (IN:SYNGENE) ) has shared an announcement.
Syngene International Ltd. announced a significant change in its senior management with the departure of Mr. Alex Del Priore, Head of Large Molecules CDMO, and the appointment of Dr. Rohtash Kumar as the new Head of CDMO for both small and large molecules. This transition is expected to strengthen Syngene’s capabilities in pharmaceutical operations, leveraging Dr. Kumar’s extensive experience in R&D and manufacturing, which could enhance the company’s competitive positioning in the global CDMO market.
More about Syngene International Ltd.
Syngene International Ltd. operates in the biotechnology industry, focusing on contract research, development, and manufacturing services. It specializes in providing solutions for small and large molecule development, catering to pharmaceutical and biotechnology companies globally.
Average Trading Volume: 64,564
Technical Sentiment Signal: Hold
Current Market Cap: 263.6B INR
See more insights into SYNGENE stock on TipRanks’ Stock Analysis page.